Glycogen Synthase Kinase-3β, NLRP3 Inflammasome, and Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is the most prevalent cause of dementia worldwide. Because of the progressive neurodegeneration, individual cognitive and behavioral functions are impaired, affecting the quality of life of millions of people. Although the exact pathogenesis of AD has not been fully elucidated, amyloid plaques, neurofibrillary tangles (NFTs), and sustaining neuroinflammation dominate its characteristics. As one of the major tau kinases leading to hyperphosphorylation and aggregation of tau, glycogen synthase kinase-3β (GSK-3β) has been drawing great attention in various AD studies. Another research focus of AD in recent years is the inflammasome, a multiprotein complex acting as a regulator in immunological reactions to exogenous and endogenous danger signals, of which the Nod-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) inflammasome has been studied mostly in AD and proven to play a significant role in AD development by its activation and downstream effects such as caspase-1 maturation and interleukin (IL)-1β release. Studies have shown that the NLRP3 inflammasome is activated in a GSK-3β-dependent way and that inhibition of the NLRP3 inflammasome downregulates GSK-3β, suggesting that these two important proteins are closely related. This article reviews the respective roles of GSK-3β and the NLRP3 inflammasome in AD as well as their relationship and interaction.

Keywords

glycogen synthase kinase-3β / NLRP3 inflammasome / Alzheimer’s disease

References

[1] GauthierS, WebsterC, ServaesSWorld Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support, 2022, London, Alzheimer’s Disease International

[2] TakashimaA. GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis JAD, 2006, 9(3Suppl): 309-317

[3] KimuraT, IshiguroK, HisanagaSI. Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci, 2014, 7: 65

[4] JiaL, DuY, ChuL, et al.. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health, 2020, 5(12): e661-e671

[5] TiraboschiP, HansenLA, MasliahE, et al.. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology, 2004, 62(11): 1977-1983

[6] PengX, GuoH, ZhangX, et al.. TREM2 Inhibits Tau Hyperphosphorylation and Neuronal Apoptosis via the PI3K/Akt/GSK-3β Signaling Pathway In vivo and In vitro. Mol Neurobiol, 2023, 60(5): 2470-2485

[7] SinghRB, RastogiSS, RaoPV, et al.. Diet and lifestyle guidelines and desirable levels of risk factors for the prevention of diabetes and its vascular complications in Indians: a scientific statement of The International College of Nutrition. Indian Consensus Group for the Prevention of Diabetes. J Cardiovasc Risk, 1997, 4(3): 201-208

[8] ParksAL, CurtisD. Presenilin diversifies its portfolio. Trends Genet, 2007, 23(3): 140-150

[9] BraiE, Alina RaioN, AlberiL. Notch1 hallmarks fibrillary depositions in sporadic Alzheimer’s disease. Acta Neuropathol Commun, 2016, 4(1): 64

[10] CappuccioI, CalderoneA, BuscetiCL, et al.. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci Off J Soc Neurosci, 2005, 25(10): 2647-2657

[11] YangY, ZhangZ. Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer’s Disease. Front Aging Neurosci, 2020, 12: 110

[12] BertrandFE. The cross-talk of NOTCH and GSK-3 signaling in colon and other cancers. Biochim Biophys Acta Mol Cell Res, 2020, 1867(9): 118738

[13] MaratheS, LiuS, BraiE, et al.. Notch signaling in response to excitotoxicity induces neurodegeneration via erroneous cell cycle reentry. Cell Death Differ, 2015, 22(11): 1775-1784

[14] ShadfarS, HwangCJ, LimMS, et al.. Involvement of inflammation in Alzheimer’s disease pathogenesis and therapeutic potential of anti-inflammatory agents. Arch Pharm Res, 2015, 38(12): 2106-2119

[15] IsingC, VenegasC, ZhangS, et al.. NLRP3 in-flammasome activation drives tau pathology. Nature, 2019, 575(7784): 669-673

[16] HenekaMT, KummerMP, StutzA, et al.. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature, 2013, 493(7434): 674-678

[17] ZhangX, WangR, HuD, et al.. Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer’s disease. Sci Adv, 2020, 6(49): eabb8680

[18] ZhangY, ZhaoY, ZhangJ, et al.. Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer’s Disease. Neurochem Res, 2020, 45(11): 2560-2572

[19] AmarS, BelmakerRH, AgamG. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr Pharm Des, 2011, 17(22): 2264-2277

[20] Tejeda-MuñozN, Robles-FloresM. Glycogen synthase kinase 3 in Wnt signaling pathway and cancer. IUBMB Life, 2015, 67(12): 914-922

[21] WoodgettJR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J, 1990, 9(8): 2431-2438

[22] ImahoriK, UchidaT. Physiology and pathology of tau protein kinases in relation to Alzheimer’s disease. J Biochem (Tokyo), 1997, 121(2): 179-188

[23] ChoJH, JohnsonGVW. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau’s ability to bind and stabilize microtubules. J Neurochem, 2004, 88(2): 349-358

[24] MorenoFJ, MedinaM, PérezM, et al.. Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparin (or tubulin). FEBS Lett, 1995, 372(1): 65-68

[25] ZhangY, ZhangY, AmanY, et al.. Amyloid-β toxicity modulates tau phosphorylation through the PAX6 signalling pathway. Brain J Neurol, 2021, 144(9): 2759-2770

[26] AvilaJ, WandosellF, HernándezF. Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother, 2010, 10(5): 703-710

[27] ZhangY w, ThompsonR, ZhangH, et al.. APP processing in Alzheimer’s disease. Mol Brain, 2011, 4(1): 3

[28] LyPT, WuY, ZouH, et al.. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest, 2013, 123(1): 224-235

[29] ZhangT, ChenD, LeeTH. Phosphorylation Signaling in APP Processing in Alzheimer’s Disease. Int J Mol Sci, 2019, 21(1): 209

[30] FeytC, PierrotN, TasiauxB, et al.. Phosphorylation of APP695 at Thr668 decreases gamma-cleavage and extracellular Abeta. Biochem Biophys Res Commun, 2007, 357(4): 1004-1010

[31] UemuraK, KuzuyaA, ShimozonoY, et al.. GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem, 2007, 282(21): 15823-15832

[32] WoodfieldA, GonzalesT, HelmerhorstE, et al.. Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer’s Disease. Int J Mol Sci, 2022, 23(24): 15811

[33] TerwelD, MuyllaertD, DewachterI, et al.. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol, 2008, 172(3): 786-798

[34] MagdesianMH, CarvalhoMMVF, MendesFA, et al.. Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling. J Biol Chem, 2008, 283(14): 9359-9368

[35] GieseKP. GSK-3: a key player in neurodegeneration and memory. IUBMB Life, 2009, 61(5): 516-521

[36] Llorens-MartínM, Jurado-ArjonaJ, Fuster-MatanzoA, et al.. Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. Transl Psychiatry, 2014, 4(10): e463

[37] BeurelE, JopeRS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol, 2006, 79(4): 173-189

[38] HeY, HaraH, NúñezG. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci, 2016, 41(12): 1012-1021

[39] TschoppJ, SchroderK. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol, 2010, 10(3): 210-215

[40] FengYS, TanZX, WuLY, et al.. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev, 2020, 64: 101192

[41] HalleA, HornungV, PetzoldGC, et al.. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol, 2008, 9(8): 857-865

[42] SrinivasulaSM, PoyetJL, RazmaraM, et al.. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem, 2002, 277(24): 21119-21122

[43] OjalaJO, SutinenEM, SalminenA, et al.. Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol, 2008, 205(1–2): 86-93.

[44] SutinenEM, PirttiläT, AndersonG, et al.. Proinflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation, 2012, 9: 199

[45] LiuE, ZhouQ, XieAJ, et al.. Tau acetylates and stabilizes β-catenin thereby promoting cell survival. EMBO Rep, 2020, 21(3): e48328

[46] ZhouR, YazdiAS, MenuP, et al.. A role for mitochondria in NLRP3 inflammasome activation [published correction appears in Nature. Nature, 2011, 469(7329): 221-225

[47] HanslikKL, UllandTK. The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer’s Disease. Front Neurol, 2020, 11: 570711

[48] LiuH, WuX, LuoJ, et al.. Adiponectin peptide alleviates oxidative stress and NLRP3 inflammasome activation after cerebral ischemia-reperfusion injury by regulating AMPK/GSK-3β. Exp Neurol, 2020, 329: 113302

[49] WangZ, GeY, BaoH, et al.. Redox-sensitive glycogen synthase kinase 3β-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury. Free Radic Biol Med, 2013, 65: 849-858

[50] SuL, ZhangJ, GomezH, et al.. Mitochondria ROS and mitophagy in acute kidney injury. Autophagy, 2023, 19(2): 401-414

[51] ZhengK, BaiJ, LiN, et al.. Protective effects of sirtuin 3 on titanium particle-induced osteogenic inhibition by regulating the NLRP3 inflammasome via the GSK-3β/β-catenin signalling pathway. Bioact Mater, 2021, 6(10): 3343-3357

[52] LarabiA, BarnichN, NguyenHTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy, 2020, 16(1): 38-51.

[53] ZhaoJ, WangH, HuangY, et al.. Lupus nephritis: glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice. Arthritis Rheumatol, 2015, 67(4): 1036-1044

[54] LiuW, WangH, WangY, et al.. Metabolic factors-triggered inflammatory response drives antidepressant effects of exercise in CUMS rats. Psychiatry Res, 2015, 228(3): 257-264

[55] ArumugamS, QinY, LiangZ, et al.. GSK3β mediates the spatiotemporal dynamics of NLRP3 inflammasome activation. Cell Death Differ, 2022, 29(10): 2060-2069

[56] HodsonR. Alzheimer’s disease. Nature, 2018, 559(7715): S1

[57] MdS, AlhakamyNA, AlfalehMA, et al.. Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches. J Pers Med, 2021, 11(11): 1116

[58] AlafuzoffI, IqbalK, FridenH, et al.. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol, 1987, 74(3): 209-225

[59] EmbiN, RylattDB, CohenP. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem, 1980, 107(2): 519-527

[60] NikoulinaSE, CiaraldiTP, MudaliarS, et al.. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes, 2000, 49(2): 263-271

[61] LaurettiE, DincerO, PraticòD. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res, 2020, 1867(5): 118664

[62] HuX, WuD, HeX, et al.. circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Mol Cancer, 2019, 18(1): 160

[63] WuQ, MaJ, WeiJ, et al.. lncRNA SNHG11 Promotes Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway and Oncogenic Autophagy. Mol Ther, 2021, 29(3): 1258-1278

[64] GhoshalN, SmileyJF, DeMaggioAJ, et al.. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer’s disease. Am J Pathol, 1999, 155(4): 1163-1172

[65] ZhangS, LachanceBB, MattsonMP, et al.. Glucose metabolic crosstalk and regulation in brain function and diseases. Prog Neurobiol, 2021, 204: 102089

[66] MartinL, LatypovaX, WilsonCM, et al.. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev, 2013, 12(1): 289-309

[67] ScheltensP, BlennowK, BretelerMM, et al.. Alzheimer’s disease. Lancet, 2016, 388(10043): 505-517

[68] KIDDM. Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature, 1963, 197: 192-193

[69] MartinL, LatypovaX, WilsonCM, et al.. Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev, 2013, 12(1): 289-309

[70] WangY, TianQ, HaoY, et al.. The kinase complex mTORC2 promotes the longevity of virus-specific memory CD4+ T cells by preventing ferroptosis. Nat Immunol, 2022, 23(2): 303-317

[71] LiaoS, WuJ, LiuR, et al.. A novel compound DBZ ameliorates neuroinflammation in LPS-stimulated microglia and ischemic stroke rats: Role of Akt(Ser473)/GSK3β(Ser9)-mediated Nrf2 activation. Redox Biol, 2020, 36: 101644

[72] CuadradoA, KüglerS, Lastres-BeckerI. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol, 2018, 14: 522-534

[73] LarabiA, BarnichN, NguyenHTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy, 2020, 16(1): 38-51

[74] LvH, LiuQ, WenZ, et al.. Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis. Redox Biol, 2017, 12: 311-324

[75] ZhangX, HeS, LuW, et al.. Glycogen synthase kinase-3β (GSK-3β) deficiency inactivates the NLRP3 inflammasome-mediated cell pyroptosis in LPS-treated periodontal ligament cells (PDLCs). In Vitro Cell Dev Biol Anim, 2021, 57(4): 404-414

[76] ChanEWL, KrishnansamyS, WongC, et al.. The NLRP3 inflammasome is involved in the neuroprotective mechanism of neural stem cells against microglia-mediated toxicity in SH-SY5Y cells via the attenuation of tau hyperphosphorylation and amyloidogenesis. Neurotoxicology, 2019, 70: 91-98

[77] CorcoranSE, HalaiR, CooperMA. Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950. Pharmacol Rev, 2021, 73(3): 968-1000